Geode Capital Management LLC Raises Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Geode Capital Management LLC grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,658,980 shares of the company's stock after buying an additional 165,669 shares during the period. Geode Capital Management LLC owned 2.09% of Viridian Therapeutics worth $31,809,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Alliancebernstein L.P. raised its position in shares of Viridian Therapeutics by 3.8% in the 4th quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock worth $43,842,000 after acquiring an additional 84,255 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in Viridian Therapeutics by 21.8% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,248,721 shares of the company's stock worth $23,938,000 after purchasing an additional 223,384 shares during the period. Loomis Sayles & Co. L P bought a new position in Viridian Therapeutics in the fourth quarter worth $26,845,000. BIT Capital GmbH lifted its position in Viridian Therapeutics by 239.8% during the fourth quarter. BIT Capital GmbH now owns 285,954 shares of the company's stock valued at $5,482,000 after buying an additional 201,808 shares during the period. Finally, Corebridge Financial Inc. boosted its holdings in shares of Viridian Therapeutics by 8.6% during the 4th quarter. Corebridge Financial Inc. now owns 36,336 shares of the company's stock valued at $697,000 after buying an additional 2,878 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Stock Up 4.8 %

Shares of NASDAQ:VRDN traded up $0.63 during trading on Tuesday, reaching $13.76. 984,120 shares of the stock traded hands, compared to its average volume of 1,203,358. The stock has a market cap of $1.12 billion, a P/E ratio of -3.19 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The stock has a 50-day moving average of $14.40 and a two-hundred day moving average of $18.44. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. As a group, sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.